The global hyperglycemia treatment market is expected to reach USD 500.49 Million in 2023 and is projected to exhibit a CAGR of 12.3% from 2023 to 2033. Researchers from around the world have developed oral drugs and insulin to treat hyperglycemia. As diabetes prevalence increases, new treatment methods are developed, and biotechnology and pharmaceutical investments are increasing, the hyperglycemia treatment market is expected to grow.
Approximately 8.4 million people worldwide suffer from type 1 diabetes (T1D), a disorder characterized by inadequate or no insulin production. A new generation of technology and methods is being used to develop insulins to treat diseases. For example, a protein that mimics the role of insulin has been identified in collaboration with researchers at Lilly, at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia. The discovery could lead to the creation of an oral pill that could replace insulin injections in the future.
Additionally, cryo-electron microscopy (cryo-EM) has allowed researchers to see insulin molecules in great detail with recent breakthroughs in the technique. It is believed that the researchers' discovery will provide insight into the potential for developing novel insulin receptor activators in humans, which may be used for treating diabetes by identifying new treatments to enhance insulin secretion. Furthermore, the FDA has approved Rybelsus (trade name: semaglutide) for treating type 2 diabetes, which is a viable alternative for those who are unwilling or unable to take injections.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2022) | USD 450.9 Million |
| Expected Market Value (2023) | USD 500.49 Million |
| Anticipated Forecast Value (2033) | USD 1,596 Million |
| Projected Growth Rate (2023 to 2033) | 12.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to a report from Future Market Insights (FMI), from 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.2%. A significant portion of the market's growth can also be attributed to increasing awareness of diabetes care and management, as well as to technological advancements in medical devices. Additionally, the increase in dietary factors and obesity are driving the hyperglycemia treatment Market.
A variety of clinical trials and studies are currently underway in various parts of the world in order to treat hyperglycemia. For instance, researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, have created the first therapeutic regimen for advanced alveolar soft part sarcomas (ASPS). In recent times, atezolizumab (Tecentriq) has received approval from the USA Food and Drug Administration (FDA) for treating ASPS in adults and children over 2 years who can't be operated on. A rare disease that has been challenging to treat will be greatly impacted by this approval.
As part of its diabetes treatment program, the NIH develops new drugs for patients with type 1 and type 2 diabetes. Researchers found that insulin glargine and liraglutide performed best among four commonly used drugs to treat type 2 diabetes in a large clinical trial. To maintain blood glucose levels in the recommended range. Blood glucose levels are maintained within the recommended range by the USA Food and Drug Administration. Metformin, the first-line drug for treating type 2 diabetes, was added to treatment with all four medications evaluated. In addition to being funded by the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases sponsored the study. The global demand for hyperglycemia treatment is projected to increase at a CAGR of 12.3% during the forecast period between 2023 and 2033, reaching a total of USD 1,596 Million in 2033.
A Major Boost for New Therapeutic Development Occurred During the Pandemic Crisis
A growing number of technological innovations and artificial intelligence are expected to boost the market for hyperglycemia treatments. A great deal of awareness has been raised over the years and a number of initiatives have been taken to help manage and maintain normal diabetic levels. Different innovative technologies for reversal programs, technological apps, and advancements in drugs have all helped to expand the market.
Various insurance plans and reimbursement policies are also expected to contribute to the growth of the market. There are an increasing number of gadgets and tools in the market now that are being designed and tested to detect the level of sugar present in a person's body before they are placed on the market. For instance, a new method of testing glucose levels has been discovered without constantly pricking the finger. A new glucose sensor that sits beneath the skin's surface has been tested by the Ulsan National Institute of Science and Technology (UNIST). As wearable technologies evolve in the market, it will be easier to monitor blood sugar levels in people with diabetes.
The development of New Therapies and Drugs will drive the Growth of the Market in the Future
Researchers and studies are being conducted to discover new drugs to reverse the diabetic damage caused to millions of people around the world. In addition to viral infections and acute illnesses, new-onset diabetes has been observed after hospital admission. Observing COVID-19-related new-onset diabetes offers a new opportunity for epidemiological and interventional research studies, allowing for a long-term follow-up of these patients. The CoviDIAB Project has been established by an international team of researchers with the aim of collecting data on diabetes caused by COVID-19 that is newly diagnosed. The COVID-19 epidemiology is expected to be further investigated through international collaborative research programs.
Principal Consultant
Delay in Diagnosis of Hyperglycemia Contributes to Hinder Growth Prospects
Increasing insulin prices and the management of these drugs at home and at the store will further hinder the market's growth. Due to COVID-19, there has been a stagnated rise in hyperglycemia treatment market growth across product segments of this market. The COVID-19 lockdown also disrupted supply chains and led to business interruptions, forcing many biopharmaceutical companies to delay treatment for hyperglycemia until new batches of raw materials became available.
Moreover, after the development, testing, and approval of a hyperglycemia drug, the adoption process begins in the market, posing an obstacle to the growth of the market. Diabetes patients in the USA have a major problem with insulin affordability. Pharmacies and drug stores that stock hyperglycemic medicines face logistical challenges due to the difficulty in finding appropriate distribution channels. A larger patient pool and low awareness about proper treatments and lifestyle may also hamper growth in some countries due to logistical challenges. Taking all these factors into account, the hyperglycemia treatment market will be negatively affected by these factors
As Obesity Issues become more Prevalent, Hyperglycemia Treatment will rise in Frequency
Having a well-established healthcare system and a high awareness of cancer patients, North America is expected to hold 53% of the global healthcare market in 2023. With its high healthcare spending, high diabetes incidence, and neurological disorders, the Americas dominate the global market for treatments for hyperglycemia. Additionally, increased research and development activities and the presence of major companies have contributed to the region's growth.
Diabetes affects 11.3% of Americans, according to the USA Centers for Disease Control and Prevention (CDC). Americans under 65 are particularly affected by insulin costs because regulators and the health care system are largely private. In spite of hopes that diabetes can be treated, the epidemic is spreading in an opposite direction, resulting in longer lifespans and lower quality of life. By 2060, childhood diabetes rates are expected to increase by 60%, according to a recent CDC report.
Around the world, Lantus, a long-acting insulin, is most commonly sold in the USA. Manufacturers of diabetic drugs view it as one of their key markets for expanding global sales. The American market is dominated by Lantus, the most commonly used basal insulin worldwide. Children with diabetes and obesity are increasing in this region, driving the hyperglycemia treatment market to grow.
Changing Economic Conditions and an Increase in Hyperglycemic Patients are furthering Hyperglycemia Treatment
Due to the better distribution of networks among key players in the hyperglycemia treatment market, the European market holds the second largest market share for hyperglycemia treatment. Over the forecast period, it is forecast that the market share for hyperglycemia treatment in Europe is expected to grow to 43% with a CAGR of 4.1%.
As government agencies continue to focus on hyperglycemia and cardiovascular diseases, the treatment of these diseases is becoming increasingly important. Hyperglycemia awareness is further increasing in Europe, which may lead to a rise in the number of devices that are being used to monitor blood sugar levels. In several countries, such as the United Kingdom, France, Germany, and others countries, the rising population contributes to the market's growth. There will be more than 16% growth in the diabetic population in the European region over the next decade. By 2040, diabetes expenditure in Europe will increase to USD 174 billion among patients aged 20-79, according to the International Diabetes Federation (IDF). According to these estimates, diabetes accounts for about 9% of total healthcare expenses in Europe.
German revenues are expected to account for nearly 7% of global markets by 2033. Patients are becoming more aware of hyperglycemia since it is associated with malignancies, the economy is doing better, reimbursement schemes are improving, and hyperglycemia is more common among cancer survivors. In addition, Germany's hyperglycemia treatment market is likely to benefit from favorable regulatory environments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Growth will Increase at a Significant Rate with the Increasing Number of Insulin Therapies
The market for Insulin therapy is expected to grow at a CAGR of 6% from 2023 to 2033. A growing market for insulins is expected to emerge among patients with type 2 diabetes. Recent decades have seen a remarkable advancement in insulin therapy. In recent years, commercial versions of ultra-rapid-acting insulin analogs and ultra-long-acting insulin analogs have been developed. In addition to insulin, there are a lot of other formulations being developed. New insulin therapies are being developed and recent innovations are outlined in this review.
The development of new formulations is another important factor driving the growth of insulin therapy. For instance, Abbott announced the integration of the FreeStyle Libre ® 3 sensors with partners Ypsomed and CamDiab's mylifeTM Loop solution, enabling insulin delivery to be smarter and more automated. In the year 2023, additional European countries will be able to avail of this automated insulin delivery system (AID). This solution continuously monitors a person's glucose levels using CamDiab's CamAPS FX mobile app and Ypsomed's my life TM YpsoPump ®, with accurate 2, real-time data from Abbott's FreeStyle Libre 3 sensor.
Oral Drug Administration Demand for Hyperglycemia Treatment to Gain Traction
Based on the route of administration, the global market is segmented into oral, and topical. Revenue from oral routes of administration is expected to accumulate a market share of 45%. As a result of drug routes for treating hyperglycemia, the market has become much more aware and adaptable.
Oral hypoglycemic drugs are FDA-approved primarily for the treatment of type 2 diabetes. Several modifications to drugs and formulations have been made as a result of technological advancements and innovations over the years. As a result, the market is expected to grow during the analysis period due to the factors mentioned above. There has been a significant increase in the market for oral hyperglycemic treatment due to patient compliance and the convenience of usage of the drugs.
Some of the start-ups in the hyperglycemia treatment market include-
Glycostasis founded in the USA is a virtual company specializing in diabetes drug development. A molecule is attached to the insulin that releases insulin only when blood sugar levels rise past a certain level. The company is developing Smart insulin to combat diabetes. This reduces complications associated with diabetes and makes life easier for patients by releasing the proper dose of insulin as needed. Eli Lilly and Company operates Glycostasis as a subsidiary as of February 17, 2016.
Diabetes Management is an online platform that provides information about preventing, curing, and managing diabetes. Besides scientific research data, the platform provides diabetes prevention, treatment, and management information. Providing information aims primarily at changing the habits of people.
InsulinApp provides an intelligent way to evaluate a patient's glycemic index at the hospital. By using the solutions, physicians can create patient histories on the solutions and generate insulin prescriptions based on clinical and laboratory data to introduce the patient to hospital hyperglycemia protocols. By adjusting insulin doses according to previous capillary glycemia, physicians can adjust the patient's insulin prescription for the new medical prescription. Furthermore, it assists in deciding when a diabetic patient or one with hyperglycemia in the hospital should be discharged from the hospital.
By increasing production and meeting consumer demands, strategic partnerships can help manufacturers boost revenue and market share. Promote new products and technologies to end users so they can benefit from their use. A partnership can increase a company's production capacity by forming a strategic partnership.
Tandem Diabetes Care, Inc. is expanding its insulin delivery pump portfolio internationally. AMF Medical SA, a Swiss company that develops the Sigi Patch Pump - an ergonomic, self-contained patch pump using pre-filled insulin cartridges - is being acquired by San Diego-based Tandem on December 13. In addition to its focus on innovation, AMF Medical shares a shared passion for providing diabetes patients with easy-to-use solutions that improve their quality of life. This acquisition supports this commitment to drive growth through innovation.
In February 2023, the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) will take place in Berlin, Germany, and online, with Genprex Inc.'s research collaborators at the University of Pittsburgh presenting preclinical data demonstrating the potential of Genprex's gene therapy for Type 1 diabetes. This study presents a great opportunity for the diabetes community to learn about its results at ATTD 2023. Data from Genprex's research further supports its ability to change the course of Type 1 diabetes with its novel gene therapy.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 500.49 Million |
| Market Value in 2033 | USD 1,596 Million |
| Growth Rate | CAGR 12.3% |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment Type, Mode of Administration, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA,Canada,Brazil,Mexico,Germany,United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Novo Nordisk A/S; Merck & Company Inc.; Medtronic; Johnson & Johnson Services Inc.; Teva Pharmaceuticals Ltd.; Eli Lilly and Company; Sanofi S.A.; Bayer AG; Bristol-Myers Squibb; Abbott |
| Customization | Available Upon Request |
The hyperglycemia treatment market CAGR for 2033 is 12.3%.
The market is estimated to reach USD 1,596 million by 2033.
Novo Nordisk, Sanofi, and Eli Lilly are key market players.
The market is estimated to secure a valuation of USD 500.49 million in 2023.
The ongoing trends in the market are advanced insulin delivery systems and non-insulin therapies.
1. Executive Summary | Hyperglycemia Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Fluid Replacement 5.2. Electrolyte Replacement 5.3. Insulin Therapy 5.4. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration 6.1. Topical 6.2. Oral 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Hospitals & Clinics 7.2. Retail Pharmacy 7.3. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. Middle East and Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Novo Nordisk A/S 18.2. Merck & Company Inc. 18.3. Medtronic 18.4. Johnson & Johnson Services, Inc. 18.5. Teva Pharmaceuticals Ltd. 18.6. Eli Lilly and Company 18.7. Sanofi S.A. 18.8. Bayer AG 18.9. Bristol-Myers Squibb 18.10. Abbott 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Hyperglycemia Treatment Market
